For decades, most women with high-risk, early-stage breast cancer have been steered toward chemotherapy after surgery, enduring months of harsh side effects as insurance against the disease returning. A large clinical trial has now challenged that default, showing that a genomic test can identify a substantial share of these patients for whom chemotherapy adds little benefit, allowing them to forgo it without compromising their outcomes.
The OPTIMA trial
The findings come from OPTIMA, a phase 3 trial that enrolled more than 4,400 patients across the United Kingdom. All had early-stage, estrogen-receptor-positive, HER2-negative breast cancer that conventional measures had flagged as high clinical risk, meaning tumors with up to nine positive lymph nodes or measuring at least 30 millimeters. Under standard practice, patients in this group are routinely offered chemotherapy as a matter of course.
The results, presented at the 2026 meeting of the American Society of Clinical Oncology, were summarized by Cancer Research UK, which reported that a genomic test allowed many of these high-risk patients to skip chemotherapy while doing just as well as those who received it. The trial is notable in part for its size, since large randomized studies are what turn a promising idea about tailoring treatment into evidence solid enough to change practice.
A test that reads the tumor’s genes
At the center of the trial is a genomic assay that measures the activity of a panel of 50 genes in a tumor sample and returns a Risk of Recurrence score along with an estimated probability that the cancer will spread within ten years. Patients whose tumors produced a low score were randomly assigned either to skip chemotherapy or to receive it, so researchers could measure whether omitting treatment cost them anything. As the Breast Cancer Research Foundation noted, roughly two-thirds of the high-risk participants fell into this lower-genomic-risk category.
The distinction matters because clinical risk and biological risk are not the same thing. A tumor can look aggressive by size and lymph-node count yet carry a gene-expression profile suggesting it is unlikely to recur, and the test is designed to separate the two. That separation is the crux of the trial: it lets doctors distinguish patients whose cancer merely looks threatening from those whose biology actually warrants aggressive treatment.
Noninferior outcomes
The trial’s core result was that a test-guided strategy proved noninferior to giving chemotherapy to everyone: patients directed away from chemotherapy on the basis of their score had recurrence-free outcomes comparable to those who were treated. Investigators calculated that, for patients in the low-risk group, chemotherapy prevents at most about two recurrences for every 100 people treated, according to reporting in The ASCO Post.
That small margin is the heart of the finding. For most patients with a low genomic score, the toxicity, cost, and lost time of chemotherapy buy a benefit so slight that the treatment can reasonably be set aside. The word noninferior carries weight in oncology, because it means the less-intensive approach did not measurably worsen the outcomes that patients care about most.
What it could change
If the approach is adopted broadly, it could spare a large number of patients the nausea, fatigue, hair loss, and longer-term risks that accompany chemotherapy, while also reducing treatment costs for health systems. The result applies specifically to the estrogen-receptor-positive, HER2-negative subtype, which is the most common form of breast cancer, so the population that stands to benefit is substantial.
Access to the genomic test and its interpretation would need to become routine for the benefit to reach patients widely, and the study strengthens the case for making that testing a standard step before chemotherapy decisions rather than an optional extra reserved for uncertain cases.
Cautions and open questions
The result does not mean every high-risk patient can avoid chemotherapy, and clinical factors still weigh in each decision. Longer follow-up will continue to track whether the patients who skipped treatment remain free of recurrence over more years, since breast cancer can return well after the initial diagnosis. Specialists stress that choices should be individualized in consultation with an oncology team rather than made on a headline alone.
Still, the trial adds to a broader shift in oncology toward using a tumor’s molecular signature, rather than its outward appearance, to decide who genuinely needs aggressive treatment and who can be spared it. That shift, sometimes called de-escalation, aims to match the intensity of treatment to the real threat a cancer poses.
The economics also weigh on health systems deciding whether to fund routine genomic testing. Chemotherapy carries not only the burden of side effects but the direct costs of infusions, supportive medications, and the management of complications, so a test that safely removes it for many patients could pay for itself while improving quality of life. Proponents argue that spending on a one-time assay is modest set against the expense and toll of months of treatment that the trial suggests some patients never needed.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
